You are here

  • Home
  • Archive
  • Volume 81, Issue 2
  • Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database

Article info

Article menu

Download PDFPDF

Correspondence
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database
Free

Authors

  • Thủy Nguyễn Department of Medical Pharmacology and Toxicology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Alexandre Thibault Jacques Maria Department of Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, University of Montpellier, Medical School, Montpellier cedex 5, France IRMB Institute for Regenerative Medicine and Biotherapy, INSERM U1183, University of Montpellier, Montpellier, France PubMed articlesGoogle scholar articles
  • Chayma Ladhari Department of Medical Pharmacology and Toxicology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Pascale Palassin Department of Medical Pharmacology and Toxicology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Xavier Quantin Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Candice Lesage Department of Dermatology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Guillaume Taïeb Department of Neurology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Xavier Ayrignac Department of Neurology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Patricia Rullier Department of Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, University of Montpellier, Medical School, Montpellier cedex 5, France PubMed articlesGoogle scholar articles
  • Dominique Hillaire-Buys Department of Medical Pharmacology and Toxicology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  • Olivier Lambotte Department of Internal Medicine, Hopital Bicetre, Le Kremlin-Bicetre, France PubMed articlesGoogle scholar articles
  • Philippe Guilpain Department of Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, University of Montpellier, Medical School, Montpellier cedex 5, France IRMB Institute for Regenerative Medicine and Biotherapy, INSERM U1183, University of Montpellier, Montpellier, France PubMed articlesGoogle scholar articles
  • Jean-Luc Faillie Department of Medical Pharmacology and Toxicology, University of Montpellier, Faculty of Medicine, Montpellier, Languedoc-Roussillon, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Alexandre Thibault Jacques Maria, Internal Medicine: Multi-Organic Diseases, Local Referral Center for systemic autoimmune diseases, Montpellier University Hospital, Univ Montpellier, Medical School, Montpellier cedex 5, France; alexandremaria{at}hotmail.fr
View Full Text

Citation

Nguyễn T, Maria ATJ, Ladhari C, et al
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database
Annals of the Rheumatic Diseases 2022;81:e32.

Publication history

  • Received January 19, 2020
  • Accepted January 22, 2020
  • First published February 17, 2020.
Online issue publication 
January 12, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.